The New York Times recently spotlighted a scientific publication by Dr. Chin Hur and other ITA research staff that investigated clinical risk factors to better identify which patients should be screening for Barrett’s Esophagus.  In a case-controlled study of 434 patients with Barrett’s Esophagus, researchers found that current use of aspirin reduced the risk of Barrett’s Esophagus by almost half.  Aspirin has been documented to reduce the incidence of esophageal cancer, most likely through inhibiting the COX-2 enzyme as increased expression of COX-2 has been detected in patients with Barrett’s Esophagus and esophageal cancer.  Further studies are needed to understand more about the relationship between the dosage and duration of aspirin use and the risk of Barrett’s Esophagus.    

PCORT Alum Christophter Lathan, MD was recently featured on Crico's Clinician's Resources site. Chris discusses his research on racial and class disparities in cancer care.

In the video below, Chris tells a story highlighting the importance of listening to patients. 

© 2012 CRICO, All Rights Reserved


By Ezekiel J. Emanuel and Steven D. Pearson
If you want to know what is wrong with American health care today, exhibit A might be the two new proton beam treatment facilities the Mayo Clinic has begun building, one in Minnesota, the other in Arizona, at a cost of more than $180 million dollars each. They are part of a medical arms race for proton beam machines, which could cost taxpayers billions of dollars for a treatment that, in many cases, appears to be no better than cheaper alternatives.

NIH study examines the impact of tobacco control policies and programs, and the potential for further reduction in lung cancer deaths

Twentieth-century tobacco control programs and policies were responsible for preventing more than 795,000 lung cancer deaths in the United States from 1975 through 2000, according to an analysis funded by the National Cancer Institute (NCI), part of the National Institutes of Health.

Oct 6 (Reuters) - Starting breast cancer screening as early as age 25 may help women who carry a genetic mutation linked to a higher risk of cancer live longer, according to a U.S. study.

Researchers, whose findings were reported in the journal Cancer, looked at which breast cancer screenings -- mammogram or magnetic resonance imaging (MRI) -- were effective in women who carry the gene mutations BRCA1 and BRCA2, known to increase the risk of breast and ovarian cancer. They looked at women aged 25, 30, 35 and 40 years old.